Percutaneous thrombectomy and right ventricular mechanical circulatory support for pulmonary embolism in a coronavirus disease 2019 patient: case report, 1-year update, and echocardiographic findings

Cohen, Gerald I.; Schreiber, Theodore; Singh, Hemindermeet; Kaki, Amir

doi:10.1093/ehjcr/ytac008

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case of Cohen et al . 13 was complicated by a pulmonary embolus and required right ventricle (RV) support with the Impella RP device and anticoagulation. The case by Kaki et al .…”

Section: Resultsmentioning

confidence: 99%

Clinical indications and outcomes of Impella devices for severe cardiogenic shock in COVID-19 patients: a systematic review

Srichawla,

Kipkorir,

Sekhon

2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) can present with significant cardiac dysfunction, including cardiogenic shock. Mechanical circulatory support with an Impella device may be utilized in these patients to support and offload native right ventricle (RV) and left ventricle (LV) function. This systematic review aims to describe clinical indications, management, laboratory data, and outcomes in patients with severe cardiogenic shock from coronavirus disease 2019 (COVID-19) treated with an Impella device. Methods: A PRISMA-directed systematic review was performed and prospectively registered in PROSPERO. The databases accessed included PubMed/MEDLINE, Scopus, and ScienceDirect. Quality and risk of bias assessments were completed using the Joanna Briggs Institute (JBI) checklist for case reports. Results: A total of sixteen records were included in the qualitative synthesis. 8/16 (50%) of the patients were men. The average age was 39 years (SD: 14.7). The BiPella approach was recorded in 3/16 (18.75%). 4/16 (25%) individuals required renal replacement therapy (RRT). Single-device usage was observed in three cases; 2/16 (Impella CP; 12.5%), and 1/16 (Impella RP; 6.25%). Treatment of COVID-19 myocarditis included a wide range of antivirals and immunomodulators. 8/16 (50%) of cases needed ECMO support. Overall, only 2/16 (11.7%) individuals died. Conclusions: Sixteen reported individuals have received an Impella implanted with a mortality rate of 11.7%. Concurrent use of renal replacement therapy and ECMO implantation was often observed. Overall, the Impella device is an effective and safe strategy in the management of COVID-19-related cardiogenic shock. Future studies should include long-term results.

show abstract

“…The case of Cohen et al . 13 was complicated by a pulmonary embolus and required right ventricle (RV) support with the Impella RP device and anticoagulation. The case by Kaki et al .…”

Section: Resultsmentioning

confidence: 99%

Clinical indications and outcomes of Impella devices for severe cardiogenic shock in COVID-19 patients: a systematic review

Srichawla,

Kipkorir,

Sekhon

2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

Medical and Mechanical Circulatory Support of the Failing Right Ventricle

Yuriditsky,

Chonde,

Friedman

et al. 2023

Curr Cardiol Rep

View full text Add to dashboard Cite

Coronavirus disease 2019 and mechanical circulatory support devices: A comprehensive review

John¹,

Mishra

Nayar

et al. 2022

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) can cause circulatory shock refractory to medical therapy. Such patients can be managed with mechanical circulatory support (MCS) devices like IABP, Impella, VA ECMO, and Left Ventricular Assist Devices (LVADs). Moreover, patients on long-term durable LVADs are a special population having increased susceptibility and mortality to COVID-19 infection. In this narrative review, we searched PubMed and Medline for studies on COVID-19 patients on short-term MCS devices. We found 36 papers with 110 patients who met our review criteria, including 89 LVAD patients and 21 COVID-19 patients who needed MCS device therapy. These studies were used to extract patient demographics, clinical presentation, MCS device details, management, and outcomes. Mean age of patients with COVID-19 infection on LVADs was 60, 73% were male, and HeartMate 3 was the most common device (53%). Most patients (77.5%) needed hospitalization, and mortality was 23.6%. Among the 21 reported cases of critically ill COVID-19 patients who required MCS, the mean age was 49.8 years, 52% were women, and the most common MCS device used was VA ECMO (62%) in conjunction with an Impella for LV venting. Comorbidities were not present in 43%, but 71% had abnormal ventricular function on echocardiography. MCS is a viable option for managing severe COVID-19 infection with shock, with many reported cases of favorable outcomes.

show abstract

Percutaneous thrombectomy and right ventricular mechanical circulatory support for pulmonary embolism in a coronavirus disease 2019 patient: case report, 1-year update, and echocardiographic findings

Cited by 3 publications

References 10 publications

Clinical indications and outcomes of Impella devices for severe cardiogenic shock in COVID-19 patients: a systematic review

Clinical indications and outcomes of Impella devices for severe cardiogenic shock in COVID-19 patients: a systematic review

Medical and Mechanical Circulatory Support of the Failing Right Ventricle

Coronavirus disease 2019 and mechanical circulatory support devices: A comprehensive review

Contact Info

Product

Resources

About